by Fred Dumais | Jan 30, 2023 | News Release
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion...
by Fred Dumais | Jan 26, 2023 | News Release
In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a...
by Fred Dumais | Jan 25, 2023 | News Release
MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
by Fred Dumais | Nov 22, 2022 | News Release
Valeo’s President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of Directors MONTREAL, QUEBEC , November 21, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian...
by Fred Dumais | Nov 15, 2022 | News Release
Q4-2022 revenue guidance raised to a record $12.5M – $13.0MFiscal 2022 revenue guidance increased to a record $27.5M – $28.0M MONTREAL, QUEBEC , November 15, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian...
by Fred Dumais | Sep 14, 2022 | News Release
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDSSabizabulin also showed significant reduction of days in ICU, days...